First Financial Bankshares Inc Acquires 1,058 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

First Financial Bankshares Inc increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 17,734 shares of the company’s stock after acquiring an additional 1,058 shares during the quarter. First Financial Bankshares Inc’s holdings in Neurocrine Biosciences were worth $2,043,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in NBIX. RFP Financial Group LLC lifted its holdings in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter valued at $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences in the 1st quarter valued at $32,000. Finally, EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter worth $35,000. Institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on NBIX shares. Oppenheimer upped their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th. Jefferies Financial Group lifted their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Citigroup raised their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Insider Activity

In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Julie Cooke sold 12,632 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares in the company, valued at approximately $2,789,638.52. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,968 shares of company stock valued at $8,999,632 over the last three months. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $116.08 on Monday. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98. The firm has a market cap of $11.68 billion, a P/E ratio of 31.98 and a beta of 0.36. The business’s fifty day moving average is $122.86 and its two-hundred day moving average is $134.01.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The company had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. During the same period in the prior year, the company earned $0.95 EPS. The firm’s revenue was up 30.4% compared to the same quarter last year. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.36 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.